Results 21 to 30 of about 3,848 (142)

Levels of PIVKA-II and alpha-fetoprotein in unresectable hepatocellular carcinoma compared to healthy controls and predictive values of both markers with radiological responses after loco-regional interventions [PDF]

PeerJ, 2023
Background The significance of the current study was to determine normative levels of PIVKA-II and AFP in patients with unresectable HCC and healthy participants.
Norhanan Hamzah, Nur Karyatee Kassim, Julia Omar, Mohd Shafie Abdullah, Yeong Yeh Lee   +4 more
doaj   +2 more sources

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma

PLoS ONE, 2022
Background Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). Although the development of systemic therapies for advanced HCC has been remarkable, the role of PIVKA ...
Shun Kaneko, Masayuki Kurosaki, Kaoru Tsuchiya, Yutaka Yasui, Yuka Hayakawa, Kento Inada, Yuki Tanaka, Shun Ishido, Sakura Kirino, Koji Yamashita, Tsubasa Nobusawa, Hiroaki Matsumoto, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Yuka Takahashi, Hiroyuki Nakanishi, Namiki Izumi   +20 more
doaj   +2 more sources

Investigation of Serum PIVKA-II Levels in Patients with Helicobacter pylori Infection and Normal Group [PDF]

Iranian Journal of Colorectal Research, 2023
Background: Helicobacter pylori is a highly prevalent microorganism and risk factor for gastric cancer. In this study, we evaluated the serum levels of PIVKA-II in patients with and without H.
Seyedeh Azra Shamsdin, Hassan Akrami, Yousef Nikmanesh, Hasti Samani, Mahammad Javad Fattahi   +4 more
doaj   +1 more source

Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma

Journal of the Formosan Medical Association, 2022
Background/purpose: Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) is a diagnostic marker for hepatocellular carcinoma (HCC). Transarterial chemoembolization (TACE) is the standard management for intermediate stage HCC but lacks ...
Sung-Yin Wang, Tung-Hung Su, Bang-bin Chen, Chun-Jen Liu, Chen-Hua Liu, Hung-Chih Yang, Tai-Chung Tseng, Pei-Jer Chen, Jia-Horng Kao   +8 more
doaj   +1 more source

Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients

Frontiers in Public Health, 2022
Increased protein induced by vitamin K absence or antagonist-II (PIVKA-II) levels had been widely reported in patients with hepatocellular carcinoma (HCC) and chronic hepatitis. However, the role of PIVKA-II in hepatitis E is unclear.
Youran Chen, Yanyan Yang, Shanshan Li, Minghao Lin, Xueting Xie, Huifang Shi, Yuchun Jiang, Sijie Zheng, Hui Shao, Naibin Yang, Mingqin Lu   +10 more
doaj   +1 more source

PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma

BMC Cancer, 2021
Background Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive system and has high morbidity and mortality rates. It is essential to search new biomarkers to improve the accuracy of early HCC diagnosis.
Honglei Feng, Bole Li, Ze Li, Qian Wei, Li Ren   +4 more
doaj   +1 more source

Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma

Frontiers in Oncology, 2021
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related death worldwide. Due to the lack of efficient tools for early detection, asymptomatic HCC patients are diagnosed at an advanced stage, leading to
Yang Yang, Yang Yang, Guangbing Li, Ziwen Lu, Ziwen Lu, Yong Liu, Junjie Kong, Jun Liu, Jun Liu   +8 more
doaj   +1 more source

Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis

JGH Open, 2022
Background and Aims Prothrombin induced by vitamin K absence‐II (PIVKA‐II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha‐fetoprotein (AFP) for early disease detection.
Henry L Y Chan, Arndt Vogel, Thomas Berg, Enrico N De Toni, Masatoshi Kudo, Jörg Trojan, Anja Eiblmaier, Hanns‐Georg Klein, Johannes Kolja Hegel, Ashish Sharma, Kairat Madin, Vinzent Rolny, Marcus‐Rene Lisy, Teerha Piratvisuth   +13 more
doaj   +1 more source

Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients

Medicina, 2022
Background and Objectives: We aim to compare the diagnostic performance of Protein induced by vitamin K absence-II (PIVKA-II), a biomarker for hepatocellular carcinoma (HCC), and alpha-fetoprotein (AFP) in differentiating HCC and non-malignant high-risk (
Hana Hadi, Wan Muhammad Azfar Wan Shuaib, Raja Affendi Raja Ali, Hanita Othman   +3 more
doaj   +1 more source

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region [PDF]

Clinical and Molecular Hepatology, 2023
Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent on its cut-off levels, degree of ...
Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik Yuen Chan   +16 more
doaj   +1 more source